Novel drugs, drug sequences and combinations have improved the outcome of prostate
cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and …

Prostate cancer (PCa) is the most common male malignancy and the fifth leading cause of
cancer death in men worldwide. Prostate cancer cells are characterized by a hybrid …

The PEA3 subfamily is a subgroup of the E26 transformation-specific (ETS) family. Its
members, ETV1, ETV4, and ETV5, have been found to be overexpressed in multiple …

Spermatogenesis is a complex, multistep process that maintains male fertility and is
sustained by rare germline stem cells. Spermatogenic progression begins with …

Abstract Purpose of Review This review will examine the taxonomy of PCa subclasses
across disease states, explore the relationship among specific alterations, and highlight …

The transmembrane protease serine 2: v‑ets erythroblastosis virus E26 oncogene homolog
(TMPRSS2: ERG) gene fusion is common in prostate cancer, while its functional role is not …

Clonal dynamics and mutation burden in healthy human prostate epithelium are relevant to
prostate cancer. We sequenced whole genomes from 409 microdissections of normal …

Pseudogenes were initially regarded as “nonfunctional” genomic elements that did not have
protein-coding abilities due to several endogenous inactivating mutations. Although …

These guidelines cover a wide range of topics from prostate cancer epidemiology to
palliative care. Questions arising in daily clinical practice have been extracted and …

Drugs that target intracellular signalling pathways have markedly improved progression-free
survival of patients with cancers who were previously regarded as untreatable. However, the …